ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,509.01
0.62%
US Tech 100
19,464.40
0.97%
다우존스 지수
39,331.85
0.41%
Bitcoin
61,893.79
-1.52%
Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Carisma Therapeutics Inc (CARM)

  7. Carisma Therapeutics Inc (CARM) 뉴스

CARM

Carisma Therapeutics (CARM)

Carisma Therapeutics Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:CARM
일자시간출처헤드라인심볼기업
2024/07/0300:45Business WireCARMILA : Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L.233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des marchés financiersNASDAQ:CARMCarisma Therapeutics Inc
2024/07/0300:45Business WireCARMILA: Information Concerning the Total Number of Voting Rights and ShareNASDAQ:CARMCarisma Therapeutics Inc
2024/07/0201:48Business WireCarmila : Finalisation de l’acquisition de Galimmo SCANASDAQ:CARMCarisma Therapeutics Inc
2024/07/0201:48Business WireCarmila: Closing of the Acquisition of Galimmo SCANASDAQ:CARMCarisma Therapeutics Inc
2024/07/0120:30PR Newswire (US)Carisma Therapeutics Announces Changes to its Board of DirectorsNASDAQ:CARMCarisma Therapeutics Inc
2024/07/0114:00Business WireCarmila: Potential Stake Increase in Galimmo SCA to 99.9%NASDAQ:CARMCarisma Therapeutics Inc
2024/07/0114:00Business WireCarmila : Participation dans Galimmo SCA potentiellement portée à 99,9%NASDAQ:CARMCarisma Therapeutics Inc
2024/06/2805:30PR Newswire (US)Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with ModernaNASDAQ:CARMCarisma Therapeutics Inc
2024/06/2520:30PR Newswire (US)Carisma Therapeutics Granted FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid TumorsNASDAQ:CARMCarisma Therapeutics Inc
2024/06/2520:30PR Newswire (US)Carisma Therapeutics to Participate in the Stifel 2024 Cell Therapy ForumNASDAQ:CARMCarisma Therapeutics Inc
2024/06/1908:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CARMCarisma Therapeutics Inc
2024/06/1505:32Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CARMCarisma Therapeutics Inc
2024/06/1505:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CARMCarisma Therapeutics Inc
2024/06/1405:30PR Newswire (US)Carisma Therapeutics Announces Adjournment of Annual Meeting of StockholdersNASDAQ:CARMCarisma Therapeutics Inc
2024/06/0600:45Business WireCARMILA : Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L.233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des marchés financiersNASDAQ:CARMCarisma Therapeutics Inc
2024/06/0600:45Business WireCARMILA: Information Concerning the Total Number of Voting Rights and ShareNASDAQ:CARMCarisma Therapeutics Inc
2024/05/3020:30PR Newswire (US)Carisma Therapeutics to Participate in the Jefferies Global Healthcare ConferenceNASDAQ:CARMCarisma Therapeutics Inc
2024/05/2908:39Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:CARMCarisma Therapeutics Inc
2024/05/1620:30PR Newswire (US)Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-MonocyteNASDAQ:CARMCarisma Therapeutics Inc
2024/05/0920:52Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CARMCarisma Therapeutics Inc
2024/05/0920:41Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CARMCarisma Therapeutics Inc
2024/05/0920:30PR Newswire (US)Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:CARMCarisma Therapeutics Inc
2024/05/0900:45Business WireCarmila: Withdrawal of funds for the liquidity contractNASDAQ:CARMCarisma Therapeutics Inc
2024/05/0900:45Business WireCarmila: Réduction des moyens du contrat de liquiditéNASDAQ:CARMCarisma Therapeutics Inc
2024/05/0820:30PR Newswire (US)Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024NASDAQ:CARMCarisma Therapeutics Inc
2024/05/0800:45Business WireCARMILA : Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L.233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des marchés financiersNASDAQ:CARMCarisma Therapeutics Inc
2024/05/0800:45Business WireCARMILA: Information Concerning the Total Number of Voting Rights and ShareNASDAQ:CARMCarisma Therapeutics Inc
2024/05/0620:30PR Newswire (US)Carisma Therapeutics to Participate in The Citizens JMP Life Sciences ConferenceNASDAQ:CARMCarisma Therapeutics Inc
2024/05/0220:30PR Newswire (US)Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical OfficerNASDAQ:CARMCarisma Therapeutics Inc
2024/04/2506:05PR Newswire (US)Carisma Therapeutics Announces Upcoming Presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual MeetingNASDAQ:CARMCarisma Therapeutics Inc
 검색 관련기사 보기:NASDAQ:CARM

최근 히스토리

NYSE
KO
Coca Cola
SPI
SP500
S&P 500
NYSE
NKE
Nike
CCOM
US500
US 500
USOTC
BASFY
BASF (QX)
NASDAQ
TSLA
Tesla
NASDAQ
QQQ
Invesco QQQ Trust Series 1
USI
USTECH100
US Tech 100
FX
USDGBP
US Dollar vs Sterling
AMEX
XLF
Financial Select Sector
NYSE
MRK
Merck
COIN
BTCUSD
Bitcoin
USOTC
BNPQY
BNP Paribas (QX)
USOTC
RHHBY
Roche (QX)
COIN
ETHUSD
Ethereum
USOTC
ADDYY
Adidas (QX)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유